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Abstract
Background: Innate immunity plays a crucial role in the host defense against malaria including Plasmodium
falciparum malaria in pregnancy, but the roles of the various underlying genes and mechanisms predisposing to
the disease are poorly understood.
Methods: 98 single-nucletoide polymorphisms were genotyped in a set of 17 functionally related genes of the
complement system in 145 primiparous Ghanaian women with placental malaria, defined by placental parasitaemia
or malaria pigment, and as a control, in 124 non-affected primiparae.
Results: Placental malaria was significantly associated with SNPs in the lectin pathway genes MBL2, MASP2, FCN2
and in properdin. In particular, the main African mannose-binding lectin deficiency variant (MBL2*G57E, rs1800451)
increased the odds of placental malaria (OR 1.6; permuted p-value 0.014). In contrast, a common MASP2 mutation
(R439H, rs12085877), which reduces the activity of MBL-MASP2 complexes occurred in 33% of non-affected women
and in 22% primiparae with placental malaria (OR 0.55, permuted p-value 0.020).
Conclusions: Excessive complement activation is of importance in the pathogenesis of placental malaria by
mediating inflammation, coagulation, and endothelial dysfunction. Mutated MBL and MASP2 proteins could have
direct intrinsic effects on the susceptibility to placental malaria, in addition to their roles in regulation of
downstream complement activation.
Keywords: Lectin pathway, Mannose-binding lectin, MBL2, MASP2, Ficolin, Complement, Innate immunity, Malaria,
Placenta, Pregnancy
Background
In sub-Saharan Africa, Plasmodium falciparum infection
during pregnancy is a major cause of maternal anaemia,
preterm delivery (PD), low birth weight (LBW) and
infant mortality. In areas endemic for P. falciparum,
85 million pregnancies occur annually, and malaria-
associated LBW in Africa results in an estimated
100,000 indirect infant deaths each year [1-3]. Pregnant,
particularly primiparous, women are at increased risk. In
pregnant women, parasites expressing specific variants
of the P. falciparum Erythrocyte Membrane Protein-1
(PfEMP1) adhere to the placental endothelium lining
the intervillous space which results in placental seques-
tration of infected red blood cells. The local accumula-
tion of infected red blood cells and of malaria pigment
(haemozoin), i.e. placental malaria, triggers the infiltra-
tion of inflammatory cells and a profound pro-inflam-
matory response [4,5]. This is confronted by an
insufficient production of specific antibodies against the
parasites and their PfEMP1 binding domain. Only with
successive pregnancies, protective acquired immune
mechanisms gradually develop and expand, and the dis-
ease manifestation declines [6-8].
In conditions of lacking or weak acquired immunity,
e.g. early childhood and pregnancy, innate immune
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responses may play a predominant role in host defense
against malaria [9]. Toll-like receptors (TLRs), for
instance, are crucial mediators of innate immunity to P.
falciparum [10], and variant signalling as deduced from
functionally relevant single nucleotide polymorphisms
(SNPs) has been associated with an increased risk and/
or manifestation of malaria in pregnancy [11,12]. Over-
all, one third of the variability in susceptibility to placen-
tal malaria is thought to be due to host genetic factors
[13]. These may also include the complement system,
composed of three pathways, the classical, the lectin and
the alternative pathway.
Mannose-binding lectin (MBL, encoded by mbl2) is a
serum protein involved in the initiation of innate immune
responses by binding to microbial surface oligosacchar-
ides, and activating the lectin pathway. Upon binding,
MBL forms a complex with mannan-binding lectin serine
peptidase 2 (MASP2) that cleaves C4 and C2 to form the
C3 convertase (C4b2a). Subsequent complement activa-
tion leads to opsonization and phagocytosis of the target
microbes, as well as formation of membrane attack com-
plexes [14]. The role of MASP1 and MASP3 (encoded by
MASP1) are still debated [15]. An important function of
MASP1 is its ability to activate the alternative pathway
proenzyme pro-D to active factor D [16]. MASP2 can
also form active complexes with ficolins which bind to
acetylated carbohydrates or, e.g., to acetylated LDL. Fico-
lins also recognize deposited C-reactive protein (CRP),
and may thus collaborate with CRP in the initiation and
control of inflammatory responses [15].
MBL binds to P. falciparum-infected red blood cells
[17], and may consequently be involved in innate
immune responses and parasite clearance. MBL defi-
ciency caused by common SNPs increases the risk of
severe malaria although findings are partially inconsis-
tent [18-22]. As for (asymptomatic) placental infection,
one recent study failed to show an association with
MBL levels or MBL2 genotypes [23].
The aim of the present study was to analyse the influ-
ence of lectin pathway polymorphisms on the susceptibil-
ity to placental malaria and its manifestation. Following a
pathway-oriented approach and using Sequenom’s Mas-
saARRAY® system, SNPs of MBL2, MASPs and ficolins
(FCN) and other important complement system genes
(SERPING1, C3, CFB, CFH, CFP) were included in a
novel “complement-chip”. Because the coagulation system
may also be involved in adverse pregnancy outcomes
[24], we also included respective regulatory genes (throm-
bomodulin, thrombospondin, FLT1).
Methods
Patients
A total of 893 women attending for delivery were
recruited between January 2000 and January 2001 at the
Presbyterian Mission Hospital in Agogo, located in the
hyper-to holoendemic Ashanti Region of Ghana. The
study protocol was reviewed and approved by the Com-
mittee on Human Research Publication and Ethics,
School of Medical Sciences, University for Science and
Technology, Kumasi, Ghana, and informed consent was
obtained from all participants. Diagnostic procedures,
malariologic indices and clinical characteristics have
been described earlier [11,24]. For the present study, all
304 primiparous women with live singleton deliveries
were included. In brief, women were clinically examined,
socioeconomic data were documented, and samples of
placental intervillous and peripheral venous blood were
collected into EDTA. Malaria parasites in intervillous
blood were counted microscopically on Giemsa-stained
thick blood films per 100 high-power fields (magnifica-
tion x1,000), and the presence of leukocyte-associated
haemozoin was recorded. Placental infection was defined
as the presence of P. falciparum parasites and/or hae-
mozoin in placental thick blood films. In addition, P.
falciparum-specific PCR assays were performed [25].
Haemoglobin (Hb) was measured by a HemoCue photo-
meter (Angelholm, Sweden), and anaemia defined as Hb
< 110 g/l. Preterm delivery was defined as a gestational
age < 37 weeks, on the basis of the Finnström score
[26], and low birth-weight as < 2,500 g.
SNP selection
Based on our previous finding of an association of
MBL2 polymorphisms with severe malaria in children
[22], all lectin pathway genes as well as other relevant
downstream complement and alternative pathway genes
were chosen for genotyping [27]. Additionally, we
included genes related to the coagulation system (throm-
bomodulin, thrombospondin) and pre-eclampsia (FLT1).
In total, 17 genes were chosen for genotyping (Table 1).
For each gene, first, we selected SNPs with assumed
relevance based on published data on protein function,
activity or disease association. Secondly, we included
potentially functional nonsense and missense SNPs, and
finally, we also included some intronic, promoter or 3’
end SNPs as markers of association. We mainly focused
on SNPs with minor allele frequencies > 0.05 in both
African and European populations based on HapMap
data.
Genotyping
DNA was extracted from peripheral blood (QIAmp;
Qiagen, Germany). Twenty-seven of the samples from
304 primiparous women were excluded from genotyping
based on low DNA quality or quantity. Among the 277
samples genotyped, 8 were removed because of a geno-
typing call rate < 0.9 leaving 269 samples for the final
analyses.
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SNP genotyping was performed using Sequenom’s
MassARRAY MALDI-TOF Mass Spectrometry Compact
platform and iPLEX Gold chemistry (Sequenom Inc,
San Diego, CA) with standard protocols. A total of 98
SNPs were assayed in four multiplexes of 15 to 34 mar-
kers each. Eight SNPs that failed to meet a call rate of >
0.8 were removed. 14 SNPs (for which no previous fre-
quency data were available) were excluded due to a
minor allele frequency < 0.05, leaving 76 SNPs for the
final analyses (Table 1). Genotypes were analysed using
Sequenom’s MassARRAY Typer version 4.0 software.
All data was checked twice manually and all outlying
data or low intensity results were removed. The integrity
of control and duplicate sample results, as well as nega-
tive control samples was checked during the evaluation
process.
Statistical analysis
Analyses were performed with PLINK v1.06 [28], SPSS
(SPSS Inc., Chicago, Illinois; release 15.0, 2006) statisti-
cal software, and with R language. Hardy-Weinberg
equilibrium was tested in infected and non-infected
women separately, with the standard Chi-square test, to
identify possible genotyping problems. Associations of
placental malaria and the SNPs were tested with basic
allelic association as well as with several genotypic mod-
els (dominant, recessive, and trend included in PLINK).
In addition to the main affection status of placental
malaria, also other phenotypes were analysed, including
low birth weight, preterm birth, maternal anaemia as
well as P. falciparum positivity by microscopy or PCR
from placental or peripheral blood samples. Permutation
tests were used to adjust for multiple testing, as well as
due to the correlatedness of the tests because of linkage
disequilibrium (LD) between markers. Haplotypes were
constructed and tested with PLINK using 2-to 6-marker
sliding windows over all areas where adjacent SNPs
were located less than 10 Mb from each other.
Odds ratios (OR) along with their confidence intervals
(CIs) were estimated with PLINK and R scripts [29].
Joint ORs for two loci were evaluated by collapsing gen-
otypes to susceptibility allele carriers and non-carriers,
and combining these over both loci, resulting in just
four susceptibility classes. This was done in order to
avoid sparse class frequencies and thus overly wide con-
fidence intervals.
Finally, interactions were screened with PLINK proce-
dure epistasis, which tests all pairs of SNPs separated by
at least 1 Mb and in different chromosomes. A p-value
threshold of 0.001 was used to avoid most false posi-
tives. We acknowledge that our data is small for making
robust inference on potential interactions, therefore
these results should be considered preliminary.
Results
The characteristics of the 269 primiparous Ghanaian
women are shown in Table 2. Fifty-four percent of the
women had placental malaria, defined as the presence of
parasites or hemozoin in the intervillous placental blood
(placental parasitemia, 48%, placental hemozoin, 43%).
Table 1 Genes selected for genotyping.
HUGO Gene Symbol Gene name SNPs genotyped SNPs analysed for association
MBL2 mannose-binding lectin 2 5 3
MASP1 mannan-binding lectin serine peptidase 1 8 7
MASP2 mannan-binding lectin serine peptidase 2 11 10
FCN1 ficolin 1 9 7
FCN2 ficolin 2 9 9
FCN3 ficolin 3 3 1
SERPING1 serpin peptidase inhibitor (C1 inhibitor) 5 4
C3 complement component 3 7 5
CFB complement factor B 5 5
CFH complement factor H 8 6
CFP complement factor properdin 6 3
THBD thrombomodulin 5 1
THBS1 thrombospondin 1 4 3
THBS2 thrombospondin 2 4 4
THBS3 thrombospondin 3 2 2
THBS4 thrombospondin 4 2 2
FLT1 fms-related tyrosine kinase 1 5 4
Total number of SNPs 98 76
22 SNPs were excluded from genetic association analyses because of low minor allele frequency, poor genotyping quality, or lack of accordance with Hardy-
Weinberg equilibrium. Gene symbols and names are given as defined in the HUGO Gene Nomenclature Committee’s database
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Placental P. falciparum-PCR was positive in 66% and
maternal peripheral blood P. falciparum-PCR positive in
59% of cases. Maternal hemoglobin and child birth
weights were lower in cases with placental malaria than
in uninfected mothers (p < 0.001 and p = 0.023). Gesta-
tional age did not differ between the groups.
A total of 76 SNPs of 17 candidate genes (Table 1)
could be subjected to association analyzses. SNPs with
at least suggestive association with placental malaria
were found on the MBL2, MASP2, Ficolin 2 (FCN2) and
Complement factor properdin (CFP) genes (Table 3).
Among these SNPs, MBL2*C (G57E, rs1800451), the
main African MBL variant, which is associated with
malaria in children [22], was present with an allele fre-
quency of 36% in women with placental malaria, and
26% in controls (p = 0.01). The results suggested a
dominant effect for an increased susceptibility to placen-
tal malaria (Table 3): homozygous or heterozygous
MBL2*C was more frequently observed in women with
placental malaria (61%, 88 out of 145) than in non-
affected women (45%, 56 out of 123) resulting in an OR
of 1.8 (95% CI, 1.1-3.0) for the susceptibility allele in
our data. MBL*C is significantly associated to micro-
scopy positivity of placental blood samples, whereas
other diagnostic tests show non-significant trends in the
same direction (Table 4). MBL2*C is not associated to
low birth weight, maternal anaemia or preterm birth.
With regard to MASP2, two markers, rs12085877
(R439H, P = 0.02) and rs1033638 (3’ untranslated
region, P = 0.03), remained significantly associated with
placental malaria after permutation tests. These exon 11
variants are located only 930 bp apart (Figure 1a). In
this area, one major haplotype including both markers
and spanning from rs2273347-rs2273346 conferred
increased odds of placental malaria, with an overall p =
0.05, and for the haplotype AAGTA specifically, p =
0.021 (Table 5). However, the LD between the two
major SNPs was surprisingly weak (rs12085877-
rs1033638: r2 = 0.037); and most of the risk increase
could be attributed to R439H. This amino acid residue
is located in the activation peptide of MASP2 (Figure
1b), between the second CCP domain and the serine
protease domain, and rhe R439H mutation inhibits the
normal function of the MBL-MASP2 complex [30].
When analysed with respect to different diagnostic tests,
R439H showed strongest negative association to the pre-
sence of malaria pigment in the placenta (p = 0.008, OR
0.47, 95% CI 0.26-0.83), but was not associated to
microscopy or PCR positivity of the placenta (Table 4).
This would suggest a role of the association especially
for chronic placental infection. Also, functionality of this
mutation was supported by a non-significant trend
towards low birth weight in individuals with the 439H
variant (p = 0.057, OR = 0.51, 95% CI 0.24-0.99).
At the 5’ end of the MASP2 gene, the region
rs3765900-rs56392418-R99Q as a whole was associated
with placental malaria at p = 0.05. Specifically, haplotype
TGG was at present in 53% and 21% of women with
and without placental malaria, respectively (p = 0.0051,
Table 5; Figure 1a). None of the markers forming the
haplotype were individually associated with placental
malaria in permutation tests.
In the FCN2 gene, two SNPs showed suggestive asso-
ciations with placental malaria (Table 3). Located in
Table 2 Characteristics of 269 primiparous Ghanaian women admitted for delivery
All Placental malaria No placental malaria P-value
Number of subjects 269 145 124
Mean age, years (± SD) 21.45 (± 3.51) 21.00 (± 3.17) 21.98 (± 3.82) 0.0511
Mean maternal hemoglobin, g/l (± SD) 112.6 (± 1.82) 106.3 (± 1.76) 120.0 (± 1.61) < 0.0011
Mean birth weight, grams (± SD) 2760 (± 485) 2698 (± 485) 2833 (± 478) 0.0232
Mean gestational age, weeks (± SD) 38.11 (± 2.50) 38.07 (± 2.77) 38.16 (± 2.17) 0.811
Proportion with
> 3 antenatal care visits 0.49 0.44 0.55 0.0833
maternal anaemia (Hb < 11 g/dL) 0.41 0.55 0.24 < 0.0013
low birth weight (< 2500 g) 0.25 0.30 0.20 0.0913
preterm delivery (< 37 weeks) 0.25 0.27 0.23 0.483
Placental blood samples
PCR positive (P. falciparum) 0.66 0.95 0.32 < 0.0013
Microscopy positive (P. falciparum) 0.48 0.88 0.00 < 0.0013
Haemozin pigments present 0.43 0.80 0.00 < 0.0013
1Mann-Whitney U-test
2Student’s t-test
3Chi-square test
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intron 2 (rs3128624) and intron 3 (rs7037264), they are
separated by only 73 bp. These SNPs were not asso-
ciated to other phenotypes.
Complement factor properdin (CFP) is a positive regu-
lator of the alternative complement pathway. It had one
SNP associated with placental malaria (rs909523; allele
C; p = 0.029 after permutation; Table 3). This variant,
located in intron 6 of the gene, was not associated with
any other assessed malaria phenotype. The region
rs1048118-rs8177079-rs909523 was associated at p =
0.028, and specifically, the haplotype ATA was protec-
tive with p = 0.007 (present in 8% and 15% of women
with and without placental malaria, respectively).
As MBL forms an active complex with MASP2, the
potential interaction between the MBL2 and MASP2
genotypes was also analysed, to evaluate whether specific
allele combinations of the two could render the individual
susceptible to malaria. Placental malaria was detected in
39% of the women carrying no risk allels for MBL2
(G57E) or MASP2 (R439 wildtype), compared to 65% of
women with risk alleles at both loci (p = 0.007; OR 2.90,
95% CI 1.34-6.48. The increased risk for those with risk
alleles at both loci compared to all other individuals gave
an OR of 2.13 (95% CI 1.33-3.65, p = 0.003). These
results suggest an additive effect of both risk alleles, but
an excess risk due to interaction could not be shown.
Discussion
Recent genome-wide association studies on malaria have
had difficulties in identifying causal gene variants in
Table 3 Single marker results of allelic and genotypic association with placental malaria
Allelic
associations
Genotypic
association
Gene SNP Mutation All. freq
cases
All. freq
controls
P-value Permuted
P-value
Odds
ratio
95% CI Best genotypic
model
Empirical
p-value
MBL2 rs1800451 G57E 0.36 0.26 0.014 0.014 1.60 1.10-2.32 Dominant 0.021
MASP2 rs12085877 H439R 0.11 0.19 0.014 0.020 0.55 0.34-0.89 Allelic 0.015
MASP2 rs1033638 3’UTR 0.36 0.27 0.04 0.022 1.52 1.01-2.26 Trend 0.064
FCN2 rs3128624 Intron 2 0.67 0.62 0.198 0.204 1.27 0.88-1.81 Dominant 0.053
FCN2 rs7037264 Intron 3 0.68 0.64 0.271 0.261 1.23 0.85-1.76 Dominant 0.042
CFP rs909523 Intron 6 0.57 0.47 0.019 0.029 1.51 1.07-2.13 Trend 0.043
Table 4 Association of different phenotypes of P.falciparum placental malaria with mutations MBL2*G57E and
MASP2*R439H
MBL2*G57E (MBL2*C;
rs1800451)
MASP2*R439H
(rs12085877)
Wildtype (GG) Mutation (AA
or AG)
p-
value
OR Wildtype (CC) Mutation (TT
or TC)
p-
value
OR
Placental malaria 45.5% (56/123) 60.7% (88/145) 0.014 1.84 (1.13-3.01) 57.7% (113/196) 43.8% (32/73) 0.054 0.58
(0.33-0.99)
Maternal peripheral
blood
PCR positive 53.7% (66/123) 63.4% (92/145) 0.108 1.50 (0.92-2.45) 62.2% (122/196) 49.3% (36/73) 0.070 0.59
(0.34-1.02)
Microscopy
positive
24.8% (29/117) 29.0% (40/138) 0.482 28.9% (55/190) 22.7% (15/66) 0.423
Placental blood
PCR positive 60.2% (74/123) 70.3% (102/
145)
0.094 1.57 (0.94-2.61) 68.4% (134/196) 58.9% (43/173) 0.151
Microscopy
positive
39.0% (48/123) 54.5% (79/145) 0.014 1.86 (1.15-3.05) 49.0% (96/196) 41.1% (30/73) 0.218
Haemozin
pigments present
36.9% (45/122) 48.3% (70/145) 0.064 1.59 (0.98-2.62) 48.0% (94/196) 29.2% (21/72) 0.008 0.47
(0.26-0.83)
Low birth weight 27.0% (33/122) 24.1% (35/145) 0.673 28.6% (56/196) 16.7% (12/72) 0.057 0.51
(0.24-0.99)
Maternal anaemia 35.0% (43/123) 40.7% (59/145) 0.378 38.8% (76/196) 35.6% (26/73) 0.673
Preterm birth 27.0% (33/122) 23.4% (34/145) 0.571 23.5% (46/196) 29.2% (21/72) 0.344
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African populations due to low LD [31,32]. In the pre-
sent study, a pathway-oriented candidate gene approach
to investigate the role of innate immunity and of the
complement system in particular, deficiencies of which
are known to increase susceptibility to a wide range of
infections [33]. Genetic variants in the MBL2, MASP2,
FCN2 and CFP genes were shown to be potential risk
factors for placental malaria in Ghana. These results
thus suggest a relevant role for the lectin pathway of the
complement system in the human defense against pla-
cental malaria.
Functional MBL2 mutations interfere with the forma-
tion of oligomers and result in low serum levels of high
molecular weight MBL and impaired MBL function
[34]. Their role in malaria has been addressed in several
studies [18-22,35], and a meta-analysis including four
studies suggested an increased risk (odds ratio 1.29, 95%
CI 1.08-1.53) for malaria in patients carrying the
MBL2*C mutation [22]. The strongest association was
found in young children [22] supporting the hypothesis
that MBL is essential especially in individuals lacking
fully developed semi-immunity. In a study from Mozam-
bique, none of ten MBL2 SNPs examined were found to
be associated with placental malaria [13], but MBL2*C
was not included. The absence of association of the
other SNPs can probably be explained by the low LD in
Africans. These results suggest that the MBL2*C variant
is a risk factor for placental malaria, in addition to
infant malaria. It remains unclear, however, why such a
disadvantageous disposition is maintained at a high fre-
quency in malaria-endemic Africa; respective issues have
been discussed elsewhere [21].
Protection from malaria provides an evolutionary bene-
fit in Africa and respective SNPs can be expected to
reach polymorphic frequencies. The MASP2 mutation
R439H (rs12085877) is absent in European and Asian
populations but according to a previous study [30] and
HapMap data, its allele frequency is 9-15% in Sub-
Saharan Africa [36]. In the present study, MASP2*R439H
occurred in 27% of the women. In contrast to MBL2*C,
it was protective against placental malaria, especially
chronic infection, and a trend towards protection from
Figure 1 (a) The genetic map of the region of the MASP2 gene on chromosome 1p36.3-p36.2 is shown (a). The SNPs genotyped in this
study are marked above the exons. (b) The polypeptide chain of MASP2 is composed of an N-terminal CUB domain, followed by en EGF
domain, a second CUB domain, two CCP (complement-control protein) domains, an activation peptide, and a serine protease domain
Table 5 Haplotype associations of MASP2 and CFP2 genes for placental malaria
Gene area Overall p-value1 Specific haplotype Prevalence in cases Prevalence in controls P-value2
MASP2, exon 11
rs2273347-rs2273346 0.05 AAGTA 0.12 0.19 0.021
MASP2, 5’ end
rs3765900-rs56392418-R99Q 0.05 TGG 0.53 0.21 0.0051
CFP
rs1048118-rs8177079-rs909523 0.028 ATA 0.08 0.15 0.007
1Overall p-value for association of the haplotypes in the gene area
2P-value for association of the specific haplotype
Holmberg et al. Malaria Journal 2012, 11:61
http://www.malariajournal.com/content/11/1/61
Page 6 of 9
low birth weight was discernible. MASP2 with the R439H
mutation is able to bind to MBL, but the enzymatic activ-
ity of the complex is considerably reduced [30]. At pre-
sent, conclusive arguments are lacking for the differential
impact on placental malaria of two genetic variants which
finally lead to reduced complement activation. Thus, it
could be possible that these mutations alter the direct
intrinsic functions of MBL and MASP2 in addition to the
downstream complement activation. MBL has been
shown to stimulate phagocytosis and opsonization also in
absent of other complement components [37]. MASP2
on the other hand, is capable of promoting fibrinogen
turnover directly by cleavage of fibrinogen and indirectly
by cleavage of prothrombin, generating active thrombin
[38]. MASP2 can, in addition to MBL, interact with fico-
lins and the balance between formation of ficolin-MASP2
complexes and MBL-MASP2 complex could influence
the susceptibility of placental malaria.
Another explanation for MASP2*R439H protecting
against placental malaria could involve a curbed produc-
tion of C5a. Recent work has demonstrated that placen-
tal parasitaemia induces increased levels of this potent
pro-inflammatory peptide in primiparae [39]. Data from
adverse pregnancy outcomes in humans and from mur-
ine models of pathological pregnancies suggest that C5a
could be an important regulator of placental angiogen-
esis, and excessive C5a could lead to functional placen-
tal insufficiency by impairing adequate vascularization of
the placenta [40]. Elevated levels of C5a, however, are
considered detrimental for host innate defense including
defects in phagocyte and endothelial cell function [41].
Curbed activation in this regard could thus be beneficial.
Alternatively, these findings on a common MASP2
variant show some resemblance with deficiency in the
closely related complement receptor 1 (CR1). CR1 is
also involved in the activation and regulation of C4, and
patients with CR1 deficiency show greatly reduced roset-
ting, i.e. binding and aggregation of infected and non-
infected erythrocytes [42]. Cytoadherence is the key fea-
ture of placental malaria [2,8], and small alterations of
this process could have substantial clinical conse-
quences. Increased generation of C4b and C3b would
thus assist adherence and rosetting of malaria infected
parasites in the placenta.
As for the ficolins, two SNPs on the FCN2 gene
showed a suggestive association with placental malaria.
These FCN2 variants are located in introns and are thus
not likely to be functional themselves. On the contrary,
they might be involved in gene expression regulation or
splicing, or in LD with the actual predisposing mutations.
Downstream complement amplification of the lectin
pathway is normally activated when MASP2 cleaves C4
and C2 to form the C3 convertase (C4b2a). C2 bypass
of the lectin pathway is also possible, and involves
alternative pathway amplification where complement
factor properdin (CFP) and complement factor D (CFD)
are involved [43]. This connection of CFP to the lectin
pathway could be an explanation of its association to
placental malaria. However, the downstream amplifica-
tion and regulation of the lectin pathway is obviously
complex and yet not fully understood.
Excessive complement activation has been suggested
to play a role in the pathogenesis of severe malaria,
including cerebral malaria as well as severe malarial
anaemia, and placental malaria [27]. Through recogni-
tion of parasites by MBL and ficolins, the lectin pathway
might be able to abort infections and reduce the parasi-
temic load, but on the other hand be harmful by med-
iating excessive inflammation, coagulation, and
endothelial dysfunction. The novel finding of the protec-
tive role of the functional MASP2*R439H mutation
makes MASP2 an interesting target for drug and vaccine
development. MASP2 inhibitors need to be studied as
potential adjunctive therapy for the various manifesta-
tions of malaria [44].
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